Lexicon Pharmaceuticals, Inc. (LXRX)
LXRX Stock Price Chart
Explore Lexicon Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze LXRX price movements and trends.
LXRX Company Profile
Discover essential business fundamentals and corporate details for Lexicon Pharmaceuticals, Inc. (LXRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Apr 2000
Employees
103.00
Website
https://www.lexpharma.comCEO
Michael S. Exton
Description
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
LXRX Financial Timeline
Browse a chronological timeline of Lexicon Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.06, while revenue estimate is $4.00m.
Earnings released on 7 May 2026
EPS came in at -$0.00 surpassing the estimated -$0.04 by +93.50%, while revenue for the quarter reached $21.10m , beating expectations by +115.55%.
Earnings released on 5 Mar 2026
EPS came in at -$0.04 surpassing the estimated -$0.07 by +42.86%, while revenue for the quarter reached $5.49m , beating expectations by +74.85%.
Earnings released on 6 Nov 2025
EPS came in at -$0.04 surpassing the estimated -$0.07 by +42.86%, while revenue for the quarter reached $14.18m , beating expectations by +351.43%.
Earnings released on 6 Aug 2025
EPS came in at $0.01 surpassing the estimated -$0.08 by +112.50%, while revenue for the quarter reached $28.87m , beating expectations by +396.71%.
Earnings released on 13 May 2025
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%, while revenue for the quarter reached $1.26m , missing expectations by -3.42%.
Earnings released on 6 Mar 2025
EPS came in at -$0.09 surpassing the estimated -$0.11 by +18.18%, while revenue for the quarter reached $26.55m , beating expectations by +842.63%.
Earnings released on 12 Nov 2024
EPS came in at -$0.18 falling short of the estimated -$0.17 by -5.88%, while revenue for the quarter reached $1.75m , missing expectations by -72.99%.
Earnings released on 1 Aug 2024
EPS came in at -$0.17 surpassing the estimated -$0.18 by +5.56%, while revenue for the quarter reached $1.65m , missing expectations by -79.82%.
Earnings released on 2 May 2024
EPS came in at -$0.20 falling short of the estimated -$0.18 by -11.11%, while revenue for the quarter reached $1.13m , missing expectations by -19.29%.
Earnings released on 11 Mar 2024
EPS came in at -$0.20 surpassing the estimated -$0.23 by +13.04%, while revenue for the quarter reached $702.00k , missing expectations by -43.39%.
Earnings released on 8 Nov 2023
EPS came in at -$0.21 surpassing the estimated -$0.22 by +4.55%, while revenue for the quarter reached $162.00k , missing expectations by -96.62%.
Earnings released on 3 Aug 2023
EPS came in at -$0.22 falling short of the estimated -$0.17 by -29.41%, while revenue for the quarter reached $317.00k , missing expectations by -92.19%.
Earnings released on 2 May 2023
EPS came in at -$0.17 matching the estimated -$0.17, while revenue for the quarter reached $24.00k , missing expectations by -20.00%.
Earnings released on 2 Mar 2023
EPS came in at -$0.16 falling short of the estimated -$0.14 by -14.29%, while revenue for the quarter reached $28.00k , missing expectations by -44.00%.
Earnings released on 9 Nov 2022
EPS came in at -$0.13 surpassing the estimated -$0.15 by +13.33%, while revenue for the quarter reached $39.00k , missing expectations by -22.00%.
Earnings released on 2 Aug 2022
EPS came in at -$0.16 falling short of the estimated -$0.15 by -6.67%, while revenue for the quarter reached $35.00k , missing expectations by -65.00%.
Earnings released on 5 May 2022
EPS came in at -$0.16 matching the estimated -$0.16, while revenue for the quarter reached $37.00k , missing expectations by -26.00%.
Earnings released on 28 Feb 2022
EPS came in at -$0.17 matching the estimated -$0.17, while revenue for the quarter reached $14.00k , missing expectations by -5.26%.
Earnings released on 3 Nov 2021
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%, while revenue for the quarter reached $23.00k , missing expectations by -80.83%.
Earnings released on 30 Jul 2021
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $234.00k , beating expectations by +2.24k%.
LXRX Stock Performance
Access detailed LXRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
